Does hyperbaric oxygen improve survival in necrotising soft tissue infections?
An interesting retrospective analysis of the outcome for 341 patients with necrotising fasciitis is reported in this edition of Anaesthesia and Intensive Care by Dr Bridget Devaney and her colleagues at the Alfred Hospital in Melbourne 1 . Despite the retrospective and non-randomised nature of the study, and hence the inherent selection and other biases, a robust statistical analysis shows a survival (number needed to treat of about eight [NNT≈8]) and limb-saving (NNT≈14) benefit for hyperbaric oxygen therapy (HBOT).
An editorial overview is warranted given: i) the size of the cohort reported, ii) the high mortality rate for necrotising fasciitis 2 , iii) the weakness of previous reports of HBOT in the treatment of this illness (as well identified by these authors) and iv) to place the study into context so that clinicians can evaluate the significance of the findings in regard to their future practice. The study also illustrates some other issues of importance for intensive care practitioners, such as the declining clinical relevance and predictive utility of APACHE III scores. The authors could well have made more of this important finding.
Elemental oxygen was first independently described by Joseph Priestley and Carl Wilhelm Scheele almost 250 years ago-although, for some reason, Priestley alone is usually credited with the discovery. The relevance to human life quickly became apparent, but the potential to modify biology, and disease and injury, was late to be recognised and is still largely underdeveloped. Although a variety of charlatans and orthodox providers had used therapeutic oxygen and HBOT earlier in the 20th century, it was not until the 1960s that success with treating clostridial gas gangrene with HBOT was reported in the Netherlands 3 and the United States Navy developed a series of HBOT regimens for the decompression illnesses 4 . It could be argued that there has been no real progress in the treatment of either condition since or, for that matter, any convincing evidence of HBOT utility in other diseases and injuries. The efficacy of HBOT in carbon monoxide poisoning is still debated, although a strongly supportive and adequately powered randomised controlled trial (i.e. both short-[P=0.03; NNT=9] and long-term benefit [intention to treat, P=0.04] is apparent) 5 . Despite claims to the contrary, a benefit for HBOT in many other neurological conditions has not been established, in part because of a very large placebo effect and a related difficulty in providing a non-therapeutic sham treatment for control subjects [6] [7] [8] .
As an example of the problem in controlling studies of HBOT and identifying the extent of any placebo effect, in a randomised clinical trial of HBOT for post-concussion syndrome, a positive outcome was obtained in 25% of subjects who had no intervention, 52% of those who had HBOT and in 35% of those who had a sham treatment (P=0.008, HBOT versus no treatment; P=0.02, sham treatment versus no treatment; P=0.7, HBOT versus sham treatment) 7 . The counter-argument is that the so-called sham treatments used to date are in fact active treatments such that a new approach to controlled studies is necessary 6 .
By contrast with this pessimistic review, there is accumulating evidence for a significant and cost-beneficial role for HBOT in the treatment of many different wounds, and especially in diabetics-including cautious support from a Cochrane systematic review 9, 10 .
There are a number of reasons for the current inattention to and oversight of oxygen as a therapy. The first and most obvious is the absence of convincing clinical data and the cost of HBOT, although the number needed to harm for HBOT is very high for permanent treatment-related disability. The discipline of hyperbaric medicine is also widely pejoratively viewed, perhaps due to the early, extensive and persistent charlatanism, and the ongoing commercialisation of HBOT. Historically, HBOT could be argued to have 'promised long and delivered short'. Many doctors interested in diving medicine came to see the provision of HBOT for other conditions as a price to be paid for their primary interest and consequently were and are poor ambassadors.
Clinical trials of HBOT are logistically demanding and intrinsically confounded 8 . The effect of HBOT is complex and highly dose-dependent (i.e. intensity, duration and frequency) 11 . For example, the required dose for optimal soft tissue wound healing will vary with treatment duration as vascular density increases in the wound. Another illustration of this complexity, and hence difficulty in clinical testing, is that a cell type, such as a polymorphonuclear leukocyte, may be activated, unaffected or inhibited as the local tissue oxygen tension increases. Little wonder then the problems in setting up a 'simple' clinical study. Also, little wonder that the conditions for which HBOT is established therapy are those where the highest possible tolerable dose of HBOT is effective (i.e. anaerobic infections and the decompression illnesses). The complex pathophysiological milieu is well described by Professor Steve Thom at the University of Pennsylvania, and interested readers would be well served by close attention to his work 11 .
It is in this context that this Alfred Hospital study should be considered.
So, what to make of the subject study and what does it add to the already abundant low-scientific-level-of-clinicalstudy-based reports of benefit for HBOT in the treatment of necrotising fasciitis? 12 If I had necrotising fasciitis, I would ask for HBOT (along with culture-based antibiotics, aggressive regular surgery and high-quality supportive care). That makes me something of a hypocrite as I disagree with the authors' conclusion that a randomised controlled clinical trial of HBOT plus 'conventional' care versus 'conventional' care alone is untenable. If HBOT is an effective treatment of necrotising fasciitis, and if it is to be taken up as routine care (and hence, potentially, to save lives and limbs), then robust data from a high-quality clinical trial is essential. The Alfred Hospital analysis provides encouragement for and enables a power calculation to underpin subsequent (randomised and controlled) studies. Given the incidence of necrotising fasciitis 2 , a multi-centred approach will probably be needed. It is likely that there will be some difficulty in agreeing to a standard treatment regimen in regard to HBOT (i.e. dose, duration and frequency), whether or not to use a sham treatment (and if so, to choose a genuine non-therapeutic sham), along with coming to a consensus on the surgical approach, antibiotics and other adjuvant care. Nevertheless, it is both necessary and well overdue.
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